Skip to main content
  • Vaccine development begins with basic laboratory research.

  • 10th African Rotavirus Symposium in Bamako, Mali

  • Clinical trial for the NIH-developed Zika vaccine.

Center for Vaccine Development (CVD)

It's not too late to get a flu shot!

CVD Overview

Life-saving immunizations are one of seven great achievements in pediatric research in the past 40 years (Cheng, Monteiro et al. 2016).

Since its inception in 1974, the CVD has worked to eliminate vaccine-preventable diseases. The CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, and other infectious diseases. The faculty and global staff includes molecular biologists, microbiologists, immunologists, internists, pediatricians, epidemiologists, malariologists, and biostatisticians.

Vaccines are a powerful tool to fight infectious diseases worldwide. For over 40 years, the CVD at the University of Maryland School of Medicine (UM SOM) in Baltimore, MD has worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. The CVD is an academic enterprise engaged in the full range of vaccinology from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments.

While the main research thrust of basic research at the CVD has historically focused on bacterial enteric pathogens, rotavirus, and malaria, it has also worked more broadly on bacterial diseases, parasitic diseases, viral diseases, novel delivery systems, public health, and vaccine policy.

Learn more about us in the CVD Fact Sheet.

History


Leadership

Dr. Neuzil brings over two decades of experience in infectious diseases and vaccine science, policy, and introduction. She’s led or been involved in pivotal vaccine trials that have influenced vaccine policy worldwide. A strong advocate for translating research results into vaccine policies, she was a key driver in the many changes in the influenza policy in the United States. Internationally, her research helped shape rotavirus vaccine policy. She is an expert on influenza, rotavirus, and RSV as well as in maternal immunization, optimizing vaccine use, and overcoming barriers to sustainable vaccine uptake in low resource settings.


Mission

Harness the power of vaccines to prevent disease and save lives in the most vulnerable populations.

Studies to support meeting our mission

Connect with Us:

Kathleen Neuzil, MD, MPH
CVD Director & Deputy Director of the IGH


CVD NEWS

Thomas, K. (Nov 19, 2016). The Race for a Zika Vaccine. The New York Times. 

Kathleen Neuzil, MD, MPH was quoted in the MarketWatch online article Why You Should Schedule Your Flu Shot Now on 5 Nov 2016.

Rosângela Mezghanni, Alessio Fasano, and Marcelo Sztein will be recognized at the Entrepreneur of the Year event on 1 Nov 2016 for their 3D model patent.

Myron M. Levine, MD, DTPH received the 2017 Maxwell Finland Award given by the National Foundation for Infectious Diseases (NFID). This highly competitive award honors scientists who have made outstanding contributions to infectious disease research and public health.

Kathleen Neuzil, MD, MPH was co-author on Efficacy of a Russian-backbone Live Attenuated Influenza Vaccine Among Young Children in Bangladesh: A Randomized Controlled Trial in the 13 Oct 2016 issue of the Lancet Glob Health.

Kathleen Neuzil, MD, MPH was co-author on Efficacy of Live Attenuated Influenza Vaccine Among Children in Senegal: A Randomised Trial in the 13 Oct 2016 issue of the Lancet Global Health.

Archived News


Give to this Department